Hyperhidrosis News and Research

RSS

Research could aid in development of antiperspirants, treatment of sweat gland disorders

Solving sweat-related concerns that occur in daily life, such as hyperhidrosis and sweat smell, can improve people's quality of life.

9 May 2020

Treatment can effectively improve quality of life for people with hyperhidrosis

At least 15 million people in the U.S. experience diminished quality of life due to excessive sweating, or hyperhidrosis.

25 Jul 2019

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence.

7 Sep 2018

Excessive sweating could be hyperhidrosis that often goes undiagnosed

Hyperhidrosis is excessive sweating that is more than what is needed to regulate body temperature. About 7 million Americans suffer from hyperhidrosis, a disorder that often goes undiagnosed.

24 Mar 2017

Scientists develop in vitro stem cell-based bioassay for detecting biological activity of BoNTs

Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bioassay grown on multi-electrode arrays capable of detecting the biological activity of Clostridium botulinum neurotoxins.

28 Feb 2017

Scientist develops way to detect BoNT in biological samples

Many know Botox as a trendy way to get rid of wrinkles, but the popular drug — made from botulinum neurotoxin (BoNT) — can do more than just fill lines.

23 Sep 2016

Special review highlights benefits of using botulinum neurotoxin for treating facial wrinkles

Botox and other botulinum neurotoxin (BoNT) products are widely known for their use in treating facial wrinkles--but they can also be used to treat a wide range of non-cosmetic problems.

31 Aug 2016

Heightened levels of psychological stress associated with skin complaints in college students

College is a stressful time in the lives of students, and a new study by researchers at the Lewis Katz School of Medicine at Temple University and Temple University found that heightened levels of psychological stress are associated with skin complaints.

24 Nov 2015

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.

25 Apr 2015

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.

19 Mar 2015

Uncontrollable sweating of hyperhidrosis can have serious impact on person

Sweating is a natural function of the body to cool it down during physical exertion or from a warm environment or to even help cope with emotional situations.

23 Apr 2014

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Researchers explore the origin of sweat gland stem cells

Without sweat, we would overheat and die. In a recent paper in the journal PLOS ONE, USC faculty member Krzysztof Kobielak and a team of researchers explored the ultimate origin of this sticky, stinky but vital substance - sweat gland stem cells.

24 Oct 2013

Allergan Licenses Rights To Medytox Candidates, In Up-To-$362M Deal

...

26 Sep 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013